Privately held Soterios Pharma unveiled positive top-line Phase II data for its alopecia areata candidate STS-01 on 30 May, saying the drug could be positioned to compete with established JAK inhibitors in the underserved disease and specifically as a therapeutic option for mild-to-moderate AA, cases in which the patient has sustained less than 50% hair loss.
Key Takeaways
-
Soterios announced that its STS-01 significantly reduces severity of alopecia areata in mild-to-moderate disease.
-
The topical, with an undisclosed mechanism of action, would compete with JAK inhibitors such as Lilly/Incyte’s Olumiant and Pfizer’s Litfulo
Headed by former Shire Pharmaceuticals Group PLC exec David Fleet as CEO, Soterios says STS-01 can provide effective, safe and convenient non-steroidal topical therapy for less-severe AA. In a 158-patient trial testing four doses – 0.25%, 0.5%, 1%, 2% – versus placebo for 24 weeks, the 1% dose of STS-01 met the primary endpoint, with 75
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?